Preparing for RSV immunisation and surveillance in Europe


Start Date
End Date
IMI2 - Call 22
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
3 744 375
EFPIA in kind
3 280 012
Total Cost
7 024 387


Respiratory syncytial virus (RSV) is an infectious disease that can cause severe illness in young children as well as the elderly and people with weakened immune systems. Globally, an estimated 33 million young children are diagnosed with RSV every year, and over 3 million are hospitalised. Currently, there is no vaccine or treatment for RSV, although a number of products are in clinical trials or earlier stages of clinical development.

The aim of PROMISE is to significantly advance our understanding of RSV to aid in the design of public health strategies as well as the development and use of vaccines and therapeutics in both children and older people. It builds on the work of IMI’s RESCEU project, which has delivered significant insights and resources on RSV.

The project plans to address current knowledge gaps on RSV, such as the relationship between RSV infection and school age wheeze and asthma. They will also identify new diagnostic tools and study biological markers of RSV infection. In addition, the project will develop a surveillance network on RSV, a resource that will provide valuable information on respiratory infections in the community. Finally, PROMISE will attempt to evaluate the impact of COVID-19 on the spread of RSV, especially among older adults.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Glaxosmithkline Biologicals SA, Rixensart, Belgium
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novavax Inc, Gaithersburg, United States
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi Pasteur SA, Lyon, France
Universities, research organisations, public bodies, non-profit groups
  • Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Martin-Luther-Universitat Halle-Wittenberg, Halle (Saale), Germany
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Servizo Galego De Saude, Santiago de Compostela, Spain
  • Statens Serum Institut, Copenhagen S, Denmark
  • Stichting Nederlands Instituut Voor Onderzoek Van De Gezondheidszorg, Utrecht, Netherlands
  • Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universiteit Antwerpen, Antwerp, Belgium
  • University of Oxford, Oxford, United Kingdom
  • Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma, Turku, Finland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Stichting Resvinet, Zeist, Netherlands
  • Team - It Research SL, Barcelona, Spain
Project coordinator
Harish Nair
The University Of Edinburgh